Table 1 Participant sociodemographic and clinical characteristics
Characteristic | N = 12 |
|---|---|
Age (years), mean (SD) | 62.5 (15.2) |
Gender, n | |
Male | 4 (33) |
Female | 8 (67) |
Ethnicity, n | |
Hispanic or Latino | 2 (17) |
Not Hispanic or Latino | 8 (67) |
No response | 2 (17) |
Racial backgrounda, n | |
Black or African American | 4 (33) |
White | 7 (58) |
Other (participant specified “Hispanic”) | 1 (8) |
Marital status, n | |
Single | 1 (8) |
Married | 7 (58) |
Divorced | 3 (25) |
Widowed | 1 (8) |
Employment status, n | |
Employed, full-time | 2 (17) |
Retired | 8 (67) |
Disabled | 2 (17) |
Highest level of education, n | |
Secondary/high school | 3 (25) |
Some college | 5 (42) |
College degree | 4 (33) |
Time since diagnosis of CTEPH (years)b, mean (SD) | 4.2 (3.7) |
Most recent WHO functional classb, n | |
I | 3 (25) |
II | 6 (50) |
III | 3 (25) |
Current treatmenta,b, n | |
Oxygen | 7 (58) |
Diuretics | 10 (83) |
Anticoagulants | 12 (100) |
Soluble guanylyl cyclase stimulator | 7 (58) |
Endothelin receptor antagonists | 5 (42) |
Fibrinogen | 1 (8) |
Phosphodiesterase type 5 inhibitors | 4 (33) |
Prostacyclin/prostacyclin analogues/prostacyclin receptor agonists | 3 (25) |
Interventiona,b, n | |
BPA only | 3 (25) |
PEA surgery only | 6 (50) |
BPA and PEA surgery | 1 (8) |
Neither BPA nor PEA surgery | 2 (17) |
Comorbid conditionsa,b, n | |
None | 1 (8) |
Anxiety | 2 (17) |
Chronic obstructive pulmonary disease | 2 (17) |
Depression | 2 (17) |
Diabetes with chronic complications | 4 (33) |
Hypertension | 3 (25) |
Obstructive sleep apnea | 3 (25) |
Rheumatological disease | 1 (8) |
Other health condition(s)c | 11 (92) |